Published in Retrovirology on December 13, 2007
The in vitro loose dimer structure and rearrangements of the HIV-2 leader RNA. Nucleic Acids Res (2011) 0.94
RNA secondary structure of the feline immunodeficiency virus 5'UTR and Gag coding region. Nucleic Acids Res (2008) 0.90
HIV-2 genome dimerization is required for the correct processing of Gag: a second-site reversion in matrix can restore both processes in dimerization-impaired mutant viruses. J Virol (2012) 0.84
Conserved determinants of lentiviral genome dimerization. Retrovirology (2015) 0.83
Structural dynamics of retroviral genome and the packaging. Front Microbiol (2011) 0.83
Mechanisms of human immunodeficiency virus type 2 RNA packaging: efficient trans packaging and selection of RNA copackaging partners. J Virol (2011) 0.83
Regulation of primate lentiviral RNA dimerization by structural entrapment. Retrovirology (2008) 0.82
Randomization and in vivo selection reveal a GGRG motif essential for packaging human immunodeficiency virus type 2 RNA. J Virol (2008) 0.82
Physicochemical analysis of rotavirus segment 11 supports a 'modified panhandle' structure and not the predicted alternative tRNA-like structure (TRLS). Arch Virol (2013) 0.80
A short sequence motif in the 5' leader of the HIV-1 genome modulates extended RNA dimer formation and virus replication. J Biol Chem (2014) 0.79
Mutations in matrix and SP1 repair the packaging specificity of a Human Immunodeficiency Virus Type 1 mutant by reducing the association of Gag with spliced viral RNA. Retrovirology (2010) 0.78
HIV-2 and its role in conglutinated approach towards Acquired Immunodeficiency Syndrome (AIDS) Vaccine Development. Springerplus (2013) 0.77
Coordination of Genomic RNA Packaging with Viral Assembly in HIV-1. Viruses (2016) 0.77
Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res (2003) 77.89
Rapid and efficient site-specific mutagenesis without phenotypic selection. Methods Enzymol (1987) 66.52
Expanded sequence dependence of thermodynamic parameters improves prediction of RNA secondary structure. J Mol Biol (1999) 41.48
Mutations of RNA and protein sequences involved in human immunodeficiency virus type 1 packaging result in production of noninfectious virus. J Virol (1990) 7.90
Noninfectious human immunodeficiency virus type 1 mutants deficient in genomic RNA. J Virol (1990) 5.45
Cis elements and trans-acting factors involved in the RNA dimerization of the human immunodeficiency virus HIV-1. J Mol Biol (1990) 4.38
Structural organization of authentic, mature HIV-1 virions and cores. EMBO J (2003) 4.32
Identification of the primary site of the human immunodeficiency virus type 1 RNA dimerization in vitro. Proc Natl Acad Sci U S A (1994) 4.07
The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions. J Virol (1994) 3.95
Ordered interstrand and intrastrand DNA transfer during reverse transcription. Science (1988) 3.80
Maturation of dimeric viral RNA of Moloney murine leukemia virus. J Virol (1993) 3.78
Characterization of human immunodeficiency virus type 1 dimeric RNA from wild-type and protease-defective virions. J Virol (1994) 3.54
The human immunodeficiency virus type 1 packaging signal and major splice donor region have a conserved stable secondary structure. J Virol (1992) 3.48
RNA is a structural element in retrovirus particles. Proc Natl Acad Sci U S A (2001) 3.45
cis elements and trans-acting factors involved in dimer formation of murine leukemia virus RNA. J Virol (1990) 3.40
A mutant of human immunodeficiency virus with reduced RNA packaging and abnormal particle morphology. J Virol (1990) 3.33
A 19-nucleotide sequence upstream of the 5' major splice donor is part of the dimerization domain of human immunodeficiency virus 1 genomic RNA. Biochemistry (1994) 3.05
Role of the DIS hairpin in replication of human immunodeficiency virus type 1. J Virol (1996) 2.87
Specific binding of HIV-1 nucleocapsid protein to PSI RNA in vitro requires N-terminal zinc finger and flanking basic amino acid residues. EMBO J (1994) 2.86
Mutant human immunodeficiency virus type 1 genomes with defects in RNA dimerization or encapsidation. J Virol (1997) 2.86
Mutational analysis of cis-acting packaging signals in human immunodeficiency virus type 1 RNA. J Virol (1994) 2.68
Retroviral nucleocapsid domains mediate the specific recognition of genomic viral RNAs by chimeric Gag polyproteins during RNA packaging in vivo. J Virol (1995) 2.52
Two alternating structures of the HIV-1 leader RNA. RNA (2001) 2.47
A dual role of the putative RNA dimerization initiation site of human immunodeficiency virus type 1 in genomic RNA packaging and proviral DNA synthesis. J Virol (1996) 2.33
Structural basis for packaging the dimeric genome of Moloney murine leukaemia virus. Nature (2004) 2.05
Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage. J Virol (1998) 2.03
Mutations in the kissing-loop hairpin of human immunodeficiency virus type 1 reduce viral infectivity as well as genomic RNA packaging and dimerization. J Virol (1997) 1.68
Nonreciprocal packaging of human immunodeficiency virus type 1 and type 2 RNA: a possible role for the p2 domain of Gag in RNA encapsidation. J Virol (1998) 1.64
In vitro evidence for a long range pseudoknot in the 5'-untranslated and matrix coding regions of HIV-1 genomic RNA. J Biol Chem (2001) 1.62
Dimer initiation signal of human immunodeficiency virus type 1: its role in partner selection during RNA copackaging and its effects on recombination. J Virol (2007) 1.60
Is HIV-1 RNA dimerization a prerequisite for packaging? Yes, no, probably? Retrovirology (2004) 1.59
Mapping the RNA binding sites for human immunodeficiency virus type-1 gag and NC proteins within the complete HIV-1 and -2 untranslated leader regions. Nucleic Acids Res (1998) 1.55
Human immunodeficiency virus types 1 and 2 differ in the predominant mechanism used for selection of genomic RNA for encapsidation. J Virol (1999) 1.52
The dimer initiation sequence stem-loop of human immunodeficiency virus type 1 is dispensable for viral replication in peripheral blood mononuclear cells. J Virol (2003) 1.37
Location of cis-acting signals important for RNA encapsidation in the leader sequence of human immunodeficiency virus type 2. J Virol (1997) 1.34
Proteolytic processing of the p2/nucleocapsid cleavage site is critical for human immunodeficiency virus type 1 RNA dimer maturation. J Virol (2001) 1.33
mRNA molecules containing murine leukemia virus packaging signals are encapsidated as dimers. J Virol (2004) 1.28
Regulated HIV-2 RNA dimerization by means of alternative RNA conformations. Nucleic Acids Res (2002) 1.20
Cleavage of p15 protein in vitro by human immunodeficiency virus type 1 protease is RNA dependent. J Virol (1994) 1.18
A small and efficient dimerization/packaging signal of rat VL30 RNA and its use in murine leukemia virus-VL30-derived vectors for gene transfer. J Virol (1994) 1.16
The dimer initiation site hairpin mediates dimerization of the human immunodeficiency virus, type 2 RNA genome. J Biol Chem (2001) 1.14
Deletion mutagenesis within the dimerization initiation site of human immunodeficiency virus type 1 results in delayed processing of the p2 peptide from precursor proteins. J Virol (1999) 1.14
HIV-1 viral RNA is selected in the form of monomers that dimerize in a three-step protease-dependent process; the DIS of stem-loop 1 initiates viral RNA dimerization. J Mol Biol (2007) 1.14
Proline residues within spacer peptide p1 are important for human immunodeficiency virus type 1 infectivity, protein processing, and genomic RNA dimer stability. J Virol (2002) 1.14
Elements located upstream and downstream of the major splice donor site influence the ability of HIV-2 leader RNA to dimerize in vitro. Biochemistry (2003) 1.11
Alternate usage of two dimerization initiation sites in HIV-2 viral RNA in vitro. J Mol Biol (2002) 1.05
A structural linkage between the dimerization and encapsidation signals in HIV-2 leader RNA. RNA (2003) 1.01
The native structure of the human immunodeficiency virus type 1 RNA genome is required for the first strand transfer of reverse transcription. Virology (1998) 0.97
An extended stem-loop 1 is necessary for human immunodeficiency virus type 2 replication and affects genomic RNA encapsidation. J Virol (2007) 0.97
Minimal region sufficient for genome dimerization in the human immunodeficiency virus type 1 virion and its potential roles in the early stages of viral replication. J Virol (2007) 0.97
Effects of Gag mutation and processing on retroviral dimeric RNA maturation. J Virol (2006) 0.94
HIV-2 RNA dimerization is regulated by intramolecular interactions in vitro. RNA (2007) 0.89
Efficient inhibition of HIV-1 expression by LNA modified antisense oligonucleotides and DNAzymes targeted to functionally selected binding sites. Retrovirology (2007) 0.87
Splicing affects presentation of RNA dimerization signals in HIV-2 in vitro. Nucleic Acids Res (2004) 0.86
Impaired RNA incorporation and dimerization in live attenuated leader-variants of SIVmac239. Retrovirology (2006) 0.84
Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol (2009) 7.50
Tilt-pair analysis of images from a range of different specimens in single-particle electron cryomicroscopy. J Mol Biol (2011) 3.16
Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J Neurosci (2002) 2.80
Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc Natl Acad Sci U S A (2013) 2.27
Structure and disassembly of filaments formed by the ESCRT-III subunit Vps24. Structure (2008) 1.95
Tau filaments from human brain and from in vitro assembly of recombinant protein show cross-beta structure. Proc Natl Acad Sci U S A (2003) 1.67
Mutation E46K increases phospholipid binding and assembly into filaments of human alpha-synuclein. FEBS Lett (2004) 1.60
A structural model for maturation of the hepatitis B virus core. Proc Natl Acad Sci U S A (2005) 1.55
HIV-1 Gag-RNA interaction occurs at a perinuclear/centrosomal site; analysis by confocal microscopy and FRET. Traffic (2005) 1.46
Analysis of tau phosphorylation and truncation in a mouse model of human tauopathy. Am J Pathol (2007) 1.32
HIV Gag polyprotein: processing and early viral particle assembly. Trends Microbiol (2012) 1.26
Impact of hepatitis B virus surface protein mutations on the diagnosis of occult hepatitis B virus infection. Hepatology (2010) 1.23
White matter tauopathy with globular glial inclusions: a distinct sporadic frontotemporal lobar degeneration. J Neuropathol Exp Neurol (2008) 1.21
The tauopathy associated with mutation +3 in intron 10 of Tau: characterization of the MSTD family. Brain (2007) 1.18
Tau protein, the paired helical filament and Alzheimer's disease. J Alzheimers Dis (2006) 1.10
Sequence Determinants for Amyloid Fibrillogenesis of Human alpha-Synuclein. J Mol Biol (2007) 1.09
Human immunodeficiency virus type 1 Gag polyprotein modulates its own translation. J Virol (2006) 1.02
Tau pathology is present in vivo and develops in vitro in sensory neurons from human P301S tau transgenic mice: a system for screening drugs against tauopathies. J Neurosci (2013) 1.02
Tau inclusions in retinal ganglion cells of human P301S tau transgenic mice: effects on axonal viability. Neurobiol Aging (2009) 1.01
Lentiviral vectors for delivery of genes into neonatal and adult ventricular cardiac myocytes in vitro and in vivo. Basic Res Cardiol (2002) 1.00
Rev regulates translation of human immunodeficiency virus type 1 RNAs. J Gen Virol (2009) 0.97
In-gel probing of individual RNA conformers within a mixed population reveals a dimerization structural switch in the HIV-1 leader. Nucleic Acids Res (2013) 0.96
Rev binds specifically to a purine loop in the SL1 region of the HIV-1 leader RNA. J Biol Chem (2003) 0.95
Optimal packaging of FIV genomic RNA depends upon a conserved long-range interaction and a palindromic sequence within gag. J Mol Biol (2010) 0.94
SHAPE analysis of the FIV Leader RNA reveals a structural switch potentially controlling viral packaging and genome dimerization. Nucleic Acids Res (2011) 0.93
Abundant neuritic inclusions and microvacuolar changes in a case of diffuse Lewy body disease with the A53T mutation in the alpha-synuclein gene. Acta Neuropathol (2005) 0.92
Three-dimensional RNA structure of the major HIV-1 packaging signal region. Structure (2013) 0.91
2008 Nobel prize in medicine for discoverers of HIV. Retrovirology (2008) 0.91
Case report: Severe typhus group rickettsiosis complicated by pulmonary edema in a returning traveler from Indonesia. Am J Trop Med Hyg (2011) 0.89
XMRV, prostate cancer and chronic fatigue syndrome. Br Med Bull (2011) 0.88
The novel Tau mutation G335S: clinical, neuropathological and molecular characterization. Acta Neuropathol (2006) 0.86
Lentiviral vectors for gene delivery to normal and demyelinated white matter. Glia (2003) 0.86
Synuclein proteins of the pufferfish Fugu rubripes: sequences and functional characterization. Biochemistry (2006) 0.86
Mutation of the Rev-binding loop in the human immunodeficiency virus 1 leader causes a replication defect characterized by altered RNA trafficking and packaging. J Gen Virol (2006) 0.86
Antiviral activity of steric-block oligonucleotides targeting the HIV-1 trans-activation response and packaging signal stem-loop RNAs. Nucleosides Nucleotides Nucleic Acids (2005) 0.85
An amino-terminal segment of hantavirus nucleocapsid protein presented on hepatitis B virus core particles induces a strong and highly cross-reactive antibody response in mice. Virology (2004) 0.85
Tau and alpha-synuclein inclusions in a case of familial frontotemporal dementia and progressive aphasia. J Neuropathol Exp Neurol (2005) 0.85
Comparative structural effects of HIV-1 Gag and nucleocapsid proteins in binding to and unwinding of the viral RNA packaging signal. Biochemistry (2012) 0.84
Hepatocyte-specific gene expression from integrated lentiviral vectors. J Gene Med (2004) 0.84
HIV-2 genome dimerization is required for the correct processing of Gag: a second-site reversion in matrix can restore both processes in dimerization-impaired mutant viruses. J Virol (2012) 0.84
Functional effects of tau gene mutations deltaN296 and N296H. J Neurochem (2002) 0.83
The molecular biology of feline immunodeficiency virus (FIV). Viruses (2011) 0.83
Variable phenotypic expression and extensive tau pathology in two families with the novel tau mutation L315R. Ann Neurol (2003) 0.83
Structure of hepatitis B surface antigen from subviral tubes determined by electron cryomicroscopy. J Mol Biol (2009) 0.83
Blockade of chemokine-induced signalling inhibits CCR5-dependent HIV infection in vitro without blocking gp120/CCR5 interaction. Retrovirology (2005) 0.82
Intracellular defenses against HIV, viral evasion and novel therapeutic approaches. J Formos Med Assoc (2011) 0.82
Phenotypic variation of autosomal-dominant corticobasal degeneration. Eur Neurol (2012) 0.81
Targeting RNA-protein interactions within the human immunodeficiency virus type 1 lifecycle. Biochemistry (2013) 0.80
Tri-partite complex for axonal transport drug delivery achieves pharmacological effect. BMC Neurosci (2010) 0.80
Lentivirus-mediated gene expression. Methods Mol Biol (2007) 0.79
Human immunodeficiency virus type 2 Gag interacts specifically with PRP4, a serine-threonine kinase, and inhibits phosphorylation of splicing factor SF2. J Virol (2004) 0.79
Early-onset dementia with Lewy bodies. Brain Pathol (2004) 0.79
A cluster of Plasmodium vivax malaria in an expedition group to Ethiopia: prophylactic efficacy of atovaquone/proguanil on liver stages of P. vivax. J Infect (2012) 0.78
The human T-cell lymphotropic virus type-I dimerization initiation site forms a hairpin loop, unlike previously characterized retroviral dimerization motifs. Biochemistry (2004) 0.78
Inhibition of HIV-1 replication by oligonucleotide analogues directed to the packaging signal and trans-activating response region. Antivir Chem Chemother (2006) 0.78
Tau protein in frontotemporal dementia linked to chromosome 3 (FTD-3). J Neuropathol Exp Neurol (2003) 0.78
Functional characterization of late outgrowth endothelial progenitor cells in patients with end-stage renal failure. Transpl Int (2014) 0.78
Identification and visualization of the dimerization initiation site of the prototype lentivirus, maedi visna virus: a potential GACG tetraloop displays structural homology with the alpha- and gamma-retroviruses. Biochemistry (2005) 0.78
An update on malaria prevention, diagnosis and treatment for the returning traveller. Blood Rev (2006) 0.77
Human beta-synuclein rendered fibrillogenic by designed mutations. J Biol Chem (2010) 0.77
Anti-HIV activity of steric block oligonucleotides. Ann N Y Acad Sci (2006) 0.77
Lipidome analysis of rotavirus-infected cells confirms the close interaction of lipid droplets with viroplasms. J Gen Virol (2013) 0.77
Macromolecular assemblages - putting the pieces together. Curr Opin Struct Biol (2004) 0.77
Endovascular aortic stent graft infection with Streptococcus equi: the first documented case. Vascular (2011) 0.76
Rapamycin-induced inhibition of HTLV-I LTR activity is rescued by c-Myb. Retrovirology (2007) 0.76
Reversible parkinsonism in a patient with progressive multifocal leucoencephalopathy. J Neurol Neurosurg Psychiatry (2007) 0.75
A case of Mycoplasma hominis septic arthritis postpartum. J Infect (2007) 0.75
A husband and wife with left hand rashes. Lancet Infect Dis (2005) 0.75
Steric block high affinity oligonucleotide analogues: a new tool for mapping RNA-protein binding sites. Nucleosides Nucleotides Nucleic Acids (2008) 0.75